ArticleOncogene2003
Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer.
Article in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- Prognostic value of cyclin E expression in breast cancer: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Pooled it
- Lethal clinical outcome and immune desert contexture in refractory gastric cancer harboring CCNE1 amplification and overexpression.British journal of cancer · 2026Article
- KCNN1 promotes proliferation and metastasis of breast cancer via ERLIN2-mediated stabilization and K63-dependent ubiquitination of Cyclin B1.Carcinogenesis · 2023Article
- NUDT22 promotes cancer growth through pyrimidine salvage.Oncogene · 2023Article
- Epigenetic factors in breast cancer therapy.Frontiers in genetics · 2022Review
- ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target.Frontiers in oncology · 2021Review
- Steroid Hormone Receptors: Links With Cell Cycle Machinery and Breast Cancer Progression.Frontiers in oncology · 2021Review
- Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer.International journal of molecular sciences · 2020Article
- Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression.The Journal of steroid biochemistry and molecular biology · 2019Review
- Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy.Frontiers in endocrinology · 2019Review
- Overcoming endocrine resistance in hormone receptor-positive breast cancer.Current oncology (Toronto, Ont.) · 2018Review
- A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers.Endocrine-related cancer · 2018Review
- Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.Molecular cancer therapeutics · 2016Article
- E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.Oncotarget · 2015Article
- Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy.Annals of oncology : official journal of the European Society for Medical Oncology · 2013Article
- Downregulation of serine protease HTRA1 is associated with poor survival in breast cancer.PloS one · 2013Article
- Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?Nature reviews. Clinical oncology · 2012Review
- Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.Breast cancer research : BCR · 2011Article
- Mechanisms of endocrine resistance in breast cancer.Annual review of medicine · 2011Review
- Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.Clinical Medicine Insights. Oncology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, cyclin-E was reported to be the most prominent prognostic factor for breast cancer outcome described so far, even surpassing axillary nodal involvement. Earlier studies on the prognostic value of cyclin-E in breast cancer, however, yielded heterogeneous results. Therefore, we set out to confirm and extend these results by quantitative Taqman RT-PCR of cyclin-E levels in 277 resectable breast cancers. Cyclin-E levels were not associated with relapse-free survival (RFS) or overall survival (OS) in the total cohort of patients, or in the subset of patients without involved lymph nodes that were not treated with adjuvant systemic therapy. Besides several classical clinicopathological factors, the interaction between cyclin-E and adjuvant endocrine therapy (P=0.01, HR=3.04, 95% CI: 1.30-7.09) was found to contribute significantly in multivariate analyses. Cyclin-E levels were associated with poor RFS specifically in patients treated with adjuvant endocrine therapy (n=108, P=0.001, HR=4.01, 95% CI: 1.76-9.12), independent of estrogen receptor status. In conclusion, cyclin-E is not a pure prognostic factor in breast cancer, but rather a predictor of failure of endocrine therapy. Differences in literature on the presumed prognostic value of cyclin-E may be due to differences in treatment. Assessment of cyclin-E levels can aid in improving adjuvant treatment selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.